医学百科 - 用户贡献 [zh-cn]

CHEK2

2026-03-23T08:14:46Z

223.160.136.180：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
<strong>[[CHEK2]]</strong>（Checkpoint Kinase 2）是一种关键的<strong>[[细胞周期检查点激酶]]</strong>，编码一种多功能的丝氨酸/苏氨酸激酶。作为[[DNA损伤反应]]([[DDR]])信号通路中的核心成员，CHEK2主要受到[[ATM]]激酶的激活，进而磷酸化[[p53]]、[[BRCA1]]和[[Cdc25C]]等下游效应因子。它被视为基因组稳定性的“二级守门员”，负责调节细胞周期停滞、DNA修复及细胞凋亡。临床上，<strong>[[CHEK2生殖系突变]]</strong>被公认为多种癌症（尤其是乳腺癌、结直肠癌和前列腺癌）的<strong>[[中等外显率]]</strong>易感基因，其突变状态正日益成为肿瘤精准筛查与[[合成致死]]治疗探索的重要指标。
</p>
</div>

<div class="medical-infobox mw-collapsible" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">

<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #f0f9ff 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">CHEK2 (Chk2)</div>
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Genome Guardian Kinase · 核心参数</div>
</div>

<div class="mw-collapsible-content">
<div style="padding: 25px; text-align: center; background-color: #f8fafc;">
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center; border-radius: 8px;">CHEK2 Protein Structure:<br>FHA & Kinase Domains</div>
</div>
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">染色体定位：22q12.1</div>
</div>

<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]] ID</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">11200</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]] 符号</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">CHEK2</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">O96017</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">~61 kDa</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">蛋白功能</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">DDR/细胞周期调控</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">突变类型</th>
<td style="padding: 8px 12px; color: #1e40af; font-weight: bold;">致病性生殖系突变</td>
</tr>
</table>
</div>
</div>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：DDR 通路的接力者</h2>
<p style="margin: 15px 0; text-align: justify;">
CHEK2 的功能是作为 DNA 双链断裂（DSBs）信号转导的放大器，其分子生物学路径如下：
</p>
<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;"><strong>ATM 介导的激活：</strong> 当 DNA 发生双链断裂时，[[ATM]] 激酶迅速被招募至损伤位点，并将 CHEK2 的 Thr68 位点磷酸化，引发其二聚化及自磷酸化激活。</li>
<li style="margin-bottom: 12px;"><strong>G2/M 停滞控制：</strong> 活化的 CHEK2 磷酸化 [[Cdc25C]] 磷酸酶，导致其被排除在细胞核外，从而抑制 [[Cyclin B1/CDK1]] 复合物的活性，使细胞周期停滞在 G2/M 期以进行修复。</li>
<li style="margin-bottom: 12px;"><strong>p53 依赖型凋亡：</strong> 如果损伤无法修复，CHEK2 通过磷酸化 [[p53]] 的 Ser20 位点增强其蛋白稳定性，触发下游促凋亡基因的表达，启动“受损细胞清除”程序。</li>
</ul>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">肿瘤易感性与临床关联</h2>
<div style="overflow-x: auto; margin: 30px auto; width: 95%;">
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 30%;">相关癌种</th>
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">风险评估 (Relative Risk)</th>
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键致病突变示例</th>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[乳腺癌]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">中等风险（约 2-3 倍风险）；累积终生风险约 20-30%。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[c.1100delC]] (截短突变)</td>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[结直肠癌]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">约 1.5-2 倍风险；多见于非息肉病性家族聚集。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">I157T (错义突变)</td>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[前列腺癌]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">增加致死性前列腺癌风险，尤其在年轻患者中。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">生殖系截短变异</td>
</tr>
</table>
</div>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床干预与精准策略</h2>
<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;"><strong>筛查共识：</strong> 对于携带 CHEK2 致病变异的乳腺癌高风险女性，[[NCCN指南]] 建议从 40 岁（或早于家族最早发病年龄 10 年）开始每年进行一次乳腺 MRI 筛查。</li>
<li style="margin-bottom: 12px;"><strong>合成致死机会：</strong> 类似于 BRCA 突变，CHEK2 缺失可导致同源重组修复（HR）受损。临床正在探索将 [[PARP抑制剂]]（如奥拉帕利）用于治疗 CHEK2 缺失的晚期实体瘤。</li>
<li style="margin-bottom: 12px;"><strong>家族遗传咨询：</strong> 由于 CHEK2 呈现常染色体显性遗传，建议对一级亲属进行级联检测，尤其是存在早发性癌症史的家族。</li>
</ul>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
<ul style="margin: 0; padding-left: 20px; color: #334155; columns: 2;">
<li style="margin-bottom: 8px;">[[ATM/ATR信号通路]]</li>
<li style="margin-bottom: 8px;">[[c.1100delC]]</li>
<li style="margin-bottom: 8px;">[[Li-Fraumeni-like综合征]]</li>
<li style="margin-bottom: 8px;">[[中等外显率基因]]</li>
<li style="margin-bottom: 8px;">[[PARP抑制剂]]</li>
<li style="margin-bottom: 8px;">[[同源重组修复缺陷(HRD)]]</li>
</ul>
</div>

<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[1] <strong>Dorling L, et al. (2021).</strong> <em>Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br>
<span style="color: #475569;">[权威点评]：该项大规模人群研究明确了 CHEK2 作为乳腺癌中等外显率基因的地位，为临床多基因面板检测（MGPT）提供了基石证据。</span>
</p>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[2] <strong>Stolarova L, et al. (2023).</strong> <em>CHEK2 Germline Variants in Cancer Predisposition: Risks and Clinical Implications.</em> <strong>[[Journal of Clinical Oncology]]</strong>. [Academic Review]<br>
<span style="color: #475569;">[学术点评]：综述系统阐述了 CHEK2 不同突变位点对表型的影响差异，强调了基于变异类型的个体化风险评估的重要性。</span>
</p>
</div>

<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-size: 0.9em;">
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
CHEK2 基因组健康 · 知识图谱
</div>
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">上游激活</td>
<td style="padding: 10px 15px; color: #334155;">[[ATM]]•[[DNA双链断裂]]•[[MRE11/RAD50/NBN复合物]]</td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">下游底物</td>
<td style="padding: 10px 15px; color: #334155;">[[p53]]•[[Cdc25C]]•[[BRCA1]]•[[E2F1]]•[[PML]]</td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">临床应用</td>
<td style="padding: 10px 15px; color: #334155;">[[奥拉帕利]]•[[乳腺MRI筛查]]•[[多基因风险评估]]</td>
</tr>
<tr>
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">研究热点</td>
<td style="padding: 10px 15px; color: #334155;">[[错义突变功能鉴定]]•[[CHEK2与PARPi耐药]]•[[非乳腺癌种的致病力分析]]</td>
</tr>
</table>
</div>

</div>

伊纳沃利塞

2026-03-23T07:19:14Z

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

<div style="margin-bottom: 30px; border-bottom: 1.5px solid #000000; padding-bottom: 25px;">
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
<strong>[[Inavolisib]]</strong>（伊纳沃利塞）是一种具有独特双重作用机制的口服强效 <strong>[[PI3Kα 抑制剂]]</strong>。该药物不仅能以高度选择性阻断 <strong>[[PI3Kα]]</strong>（由 <strong>[[PIK3CA]]</strong> 基因编码）的激酶活性，还能通过 <strong>[[泛素-蛋白酶体途径]]</strong> 特异性促进突变型 <strong>[[p110α]]</strong> 蛋白的降解。作为针对 <strong>[[PIK3CA 突变]]</strong>、<strong>[[HR 阳性 / HER2 阴性]]</strong> 晚期乳腺癌的突破性药物，Inavolisib 联合内分泌治疗及 <strong>[[CDK4/6 抑制剂]]</strong> 已显著改善了患者的 <strong>[[无进展生存期]]</strong>（PFS），开启了三联方案在乳腺癌一线治疗中的新标准。
</p>
</div>

<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">

<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Inavolisib / 伊纳沃利塞</div>
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px;">PI3Kα Inhibitor & Degrader · 点击展开</div>
</div>

<div class="mw-collapsible-content" style="display: none;">
<div style="padding: 20px; text-align: center; background-color: #f8fafc;">
<div style="padding: 10px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;">
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px;">[[p110α]] [[Degrader]] [[Model]]</div>
</div>
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px;">核心靶标: <strong>[[PIK3CA]]</strong></div>
</div>

<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
<tr>
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;"><strong>[[Entrez ID]]</strong></th>
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">5290 (PIK3CA)</td>
</tr>
<tr>
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;"><strong>[[HGNC ID]]</strong></th>
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">8892</td>
</tr>
<tr>
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;"><strong>[[UniProt ID]]</strong></th>
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">P42336 (p110α)</td>
</tr>
<tr>
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">579.67 Da</td>
</tr>
<tr>
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要副作用</th>
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;"><strong>[[高血糖]]</strong>、口炎</td>
</tr>
<tr>
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569;">开发公司</th>
<td style="padding: 10px 12px;"><strong>[[罗氏]]</strong> (Genentech)</td>
</tr>
</table>
</div>
</div>

<h2 style="background: #f1f5f9; color: #000000; padding: 10px 18px; border-radius: 0 4px 4px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #000000;"><strong>药理机制：抑制与降解的双重打击</strong></h2>
<p style="margin: 15px 0; text-align: justify;">
Inavolisib 区别于第一代抑制剂（如 <strong>[[阿培利司]]</strong>）的关键在于其对突变蛋白的清除能力：
</p>

<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;">激酶活性抑制：作为一种 <strong>[[ATP 竞争性]]</strong> 抑制剂，Inavolisib 结合在 p110α 的活性口袋，阻止 <strong>[[PIP2]]</strong> 磷酸化为 <strong>[[PIP3]]</strong>，从而迅速阻断 <strong>[[AKT 信号通路]]</strong>。</li>
<li style="margin-bottom: 12px;">靶向蛋白降解：该药物展现出类似于 <strong>[[PROTAC]]</strong> 的效应，能诱导突变型 p110α 蛋白发生泛素化修饰，使其被 <strong>[[蛋白酶体]]</strong> 降解。这种机制可以更彻底地降低肿瘤细胞内的致癌信号水平，并延缓耐药的产生。</li>
<li style="margin-bottom: 12px;">亚型选择性：其对 α 亚型的选择性远高于 β、δ、γ 亚型，这种高选择性有助于在增强疗效的同时，尽可能减少非特异性的系统性毒性。</li>
</ul>

<h2 style="background: #f1f5f9; color: #000000; padding: 10px 18px; border-radius: 0 4px 4px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #000000;"><strong>临床矩阵：INAVO120 研究核心数据</strong></h2>
<div style="overflow-x: auto; margin: 25px auto;">
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
<tr style="background-color: #f8fafc; border-bottom: 2px solid #000000;">
<th style="padding: 10px; border: 1px solid #cbd5e1; width: 22%;">临床终点</th>
<th style="padding: 10px; border: 1px solid #cbd5e1;">三联治疗组 (Inavolisib 组)</th>
<th style="padding: 10px; border: 1px solid #cbd5e1;">对照组 (标准二联方案)</th>
<th style="padding: 10px; border: 1px solid #cbd5e1;">临床获益评价</th>
</tr>
<tr>
<td style="padding: 8px; border: 1px solid #cbd5e1;">中位 <strong>[[无进展生存期]]</strong></td>
<td style="padding: 8px; border: 1px solid #cbd5e1;">15.0 个月</td>
<td style="padding: 8px; border: 1px solid #cbd5e1;">7.3 个月</td>
<td style="padding: 8px; border: 1px solid #cbd5e1;">疾病进展风险降低了 57%。</td>
</tr>
<tr>
<td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>[[客观缓解率]]</strong> (ORR)</td>
<td style="padding: 8px; border: 1px solid #cbd5e1;">58.4%</td>
<td style="padding: 8px; border: 1px solid #cbd5e1;">25.0%</td>
<td style="padding: 8px; border: 1px solid #cbd5e1;">显著提升了肿瘤负荷的缩减比例。</td>
</tr>
<tr>
<td style="padding: 8px; border: 1px solid #cbd5e1;">安全性特征</td>
<td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>[[高血糖]]</strong>、<strong>[[皮疹]]</strong>、腹泻</td>
<td style="padding: 8px; border: 1px solid #cbd5e1;">血液学毒性为主</td>
<td style="padding: 8px; border: 1px solid #cbd5e1;">副作用通常通过剂量调整可控。</td>
</tr>
</table>
</div>

<h2 style="background: #f1f5f9; color: #000000; padding: 10px 18px; border-radius: 0 4px 4px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #000000;"><strong>治疗策略：突变导向的一线三联方案</strong></h2>
<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;">伴随诊断的重要性：在使用 Inavolisib 前，必须通过 <strong>[[组织活检]]</strong> 或 <strong>[[液体活检]]</strong> 明确患者是否存在 <strong>[[PIK3CA 突变]]</strong>。</li>
<li style="margin-bottom: 12px;">联合用药模式：目前的标准临床路径是 Inavolisib 联合 <strong>[[帕博西尼]]</strong>（Palbociclib）及 <strong>[[氟维司群]]</strong>（Fulvestrant）。这种三联方案通过同时阻断激素信号、细胞周期信号和 PI3K 代谢信号，实现了协同增效。</li>
<li style="margin-bottom: 12px;">代谢不良反应监控：由于 PI3Kα 直接参与胰岛素信号传导，用药期间需严密监测 <strong>[[糖化血红蛋白]]</strong>（HbA1c）和空腹血糖，必要时联用 <strong>[[二甲双胍]]</strong> 进行血糖管理。</li>
</ul>

<div style="margin: 40px 0; border: 1.2px solid #e2e8f0; border-radius: 10px; padding: 25px; background-color: #ffffff;">
<h3 style="margin-top: 0; color: #000000; font-size: 1.15em; margin-bottom: 20px; border-bottom: 2px solid #000000; display: inline-block; padding-bottom: 5px;"><strong>关键相关概念</strong></h3>
<div style="display: flex; flex-direction: column; gap: 12px; font-size: 0.95em;">
<div style="color: #334155;"><strong>[[PIK3CA]]</strong>：编码 PI3K 催化亚基 p110α 的基因，乳腺癌中最常见的致癌突变基因。</div>
<div style="color: #334155;"><strong>[[INAVO120]]</strong>：确立 Inavolisib 联合方案在乳腺癌一线治疗地位的关键 III 期临床试验。</div>
<div style="color: #334155;"><strong>[[阿培利司]]</strong>：全球首个获批的 PI3Kα 抑制剂，是该领域的重要对照药物。</div>
<div style="color: #334155;"><strong>[[高血糖]]</strong>：PI3Kα 抑制剂最核心的药理相关毒性，需进行全流程管理。</div>
</div>
</div>

<div style="font-size: 0.9em; line-height: 1.7; color: #1e293b; margin-top: 50px; border-top: 2.5px solid #000000; padding-top: 25px; text-align: left;">
<span style="color: #000000; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;"><strong>学术参考文献与权威点评</strong></span>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[1] <strong>Turner NC, et al. (2024).</strong> <em>Inavolisib-based therapy in HER2-negative advanced breast cancer with PIK3CA mutation.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br>
<span style="color: #475569;">[学术点评]：该研究结果改写了乳腺癌的一线治疗标准，双重机制带来的 PFS 获益极具临床价值。</span>
</p>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[2] <strong>Janku F, et al. (2022).</strong> <em>Targeting PIK3CA mutations in cancer: The next generation of inhibitors.</em> <strong>[[Nature Reviews Clinical Oncology]]</strong>.<br>
<span style="color: #475569;">[学术点评]：[Academic Review] 该文献详述了从泛抑制向蛋白降解策略演进的药理学必然性。</span>
</p>
</div>

<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
<div style="background-color: #f1f5f9; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: left; border-bottom: 1px solid #e2e8f0;">
<strong>Inavolisib & PI3K 靶向药物 · 知识图谱导航</strong>
</div>
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">分子靶向</td>
<td style="padding: 10px 15px; color: #334155; text-align: left;"><strong>[[PIK3CA]]</strong> • <strong>[[p110α]]</strong> • <strong>[[PIP3]]</strong> • <strong>[[AKT]]</strong> • <strong>[[mTOR]]</strong></td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">临床标杆</td>
<td style="padding: 10px 15px; color: #334155; text-align: left;"><strong>[[Itovebi]]</strong> • <strong>[[阿培利司]]</strong> • <strong>[[度维利塞]]</strong> • <strong>[[科潘利司]]</strong></td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">关联机制</td>
<td style="padding: 10px 15px; color: #334155; text-align: left;"><strong>[[内分泌耐药]]</strong> • <strong>[[蛋白降解]]</strong> • <strong>[[三联方案]]</strong> • <strong>[[伴随诊断]]</strong></td>
</tr>
</table>
</div>

</div>

Vepdegestrant

2026-03-23T07:18:11Z

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
<strong>[[Vepdegestrant]]</strong>，研发代码为<strong>[[ARV-471]]</strong>，是由Arvinas与[[辉瑞]]([[Pfizer]])联合开发的一种口服、高选择性的<strong>[[PROTAC]]（蛋白降解靶向联合体）</strong>。作为一种新型的<strong>[[雌激素受体]]([[ER]])降解剂</strong>，Vepdegestrant通过招募E3泛素连接酶，利用细胞自身的蛋白酶体系统诱导ER蛋白的泛素化与降解。与传统的[[SERM]]（如他莫昔芬）或[[SERD]]（如氟维司群）不同，Vepdegestrant能更彻底地清除靶蛋白，尤其是在处理含有<strong>[[ESR1突变]]</strong>的耐药性<strong>[[ER阳性/HER2阴性乳腺癌]]</strong>中展现出卓越的临床潜力。
</p>
</div>

<div class="medical-infobox mw-collapsible" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">

<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #f0f9ff 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Vepdegestrant (ARV-471)</div>
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">ER PROTAC Degrader · 核心参数</div>
</div>

<div class="mw-collapsible-content">
<div style="padding: 25px; text-align: center; background-color: #f8fafc;">
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center; border-radius: 8px;">Mechanism: Targeted Estrogen Receptor Degradation via PROTAC</div>
</div>
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[ER]] ([[ESR1]])</div>
</div>

<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]] ID</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2099</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]] 符号</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">ESR1</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P03372</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">CAS号</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2244837-41-4</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">口服 PROTAC</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">开发阶段</th>
<td style="padding: 8px 12px; color: #1e40af; font-weight: bold;">临床 III 期 (VERITAC-2)</td>
</tr>
</table>
</div>
</div>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：蛋白降解的革新</h2>

<p style="margin: 15px 0; text-align: justify;">
Vepdegestrant的设计采用了经典的[[PROTAC]]双功能分子结构，一端结合雌激素受体（ER），另一端结合[[VHL]] E3泛素连接酶：
</p>
<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;"><strong>三元复合物形成：</strong> 药物作为“桥梁”促成ER蛋白与E3连接酶的物理接触。</li>
<li style="margin-bottom: 12px;"><strong>蛋白酶体途径：</strong> E3连接酶催化ER蛋白的泛素化，随后该受体被输送至[[蛋白酶体]]进行降解。</li>
<li style="margin-bottom: 12px;"><strong>高效循环：</strong> 一分子Vepdegestrant可以催化多个ER分子的降解，具有催化活性，这使其在较低浓度下即可实现比竞争性抑制剂更彻底的受体阻断。</li>
<li style="margin-bottom: 12px;"><strong>针对ESR1突变：</strong> 临床前数据显示，Vepdegestrant对包括Y537S和D538G在内的常见[[ESR1]]抗性突变体具有强劲的降解能力。</li>
</ul>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床研究概览</h2>
<div style="overflow-x: auto; margin: 30px auto; width: 95%;">
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">研究名称</th>
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">研究设计/人群</th>
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键发现/地位</th>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[VERITAC]] (Ph 1/2)</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">重度经治的ER+/HER2-晚期乳腺癌。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">在ESR1突变患者中临床获益率（CBR）显著，耐受性良好。</td>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[VERITAC-2]] (Ph 3)</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">对比氟维司群，用于内分泌治疗后的晚期患者。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">旨在确立其作为新一代标准内分泌治疗（ET）的地位。</td>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[联合方案探索]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">联合[[哌柏西利]](CDK4/6i)或新型靶向药。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">探索在一线或二线治疗中强化ER通路阻断的可能性。</td>
</tr>
</table>
</div>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床意义与应用挑战</h2>

<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;"><strong>克服内分泌耐药：</strong> Vepdegestrant为CDK4/6抑制剂和芳香化酶抑制剂（AI）耐药后的患者提供了关键的后续选择。</li>
<li style="margin-bottom: 12px;"><strong>口服便利性：</strong> 相比需要每月肌肉注射的氟维司群，口服给药极大提升了患者的依从性和生活质量。</li>
<li style="margin-bottom: 12px;"><strong>安全性关注：</strong> 临床观察到的主要不良反应包括疲劳、恶心和关节痛，整体安全性谱系与传统内分泌药物相似，但需关注PROTAC类药物特有的长效代谢特征。</li>
</ul>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
<ul style="margin: 0; padding-left: 20px; color: #334155; columns: 2;">
<li style="margin-bottom: 8px;">[[PROTAC]]</li>
<li style="margin-bottom: 8px;">[[ESR1突变]]</li>
<li style="margin-bottom: 8px;">[[口服SERD]] ([[Elacestrant]])</li>
<li style="margin-bottom: 8px;">[[蛋白酶体降解]]</li>
<li style="margin-bottom: 8px;">[[VHL E3连接酶]]</li>
<li style="margin-bottom: 8px;">[[内分泌耐药]]</li>
</ul>
</div>

<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[1] <strong>Snyder LB, et al. (2021).</strong> <em>The discovery of ARV-471, a potent and orally bioavailable PROTAC degrader of ER.</em> <strong>[[AACR Annual Meeting]]</strong>.<br>
<span style="color: #475569;">[学术点评]：该报告首次揭示了ARV-471在临床前模型中优于氟维司群的降解活性，开启了PROTAC在乳腺癌领域的应用。</span>
</p>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[2] <strong>Schott AF, et al. (2022).</strong> <em>ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/HER2- metastatic breast cancer.</em> <strong>[[SABCS]]</strong>. [Academic Review]<br>
<span style="color: #475569;">[权威点评]：VERITAC研究的数据确立了Vepdegestrant在ESR1突变型晚期乳腺癌中的治疗潜力。</span>
</p>
</div>

<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-size: 0.9em;">
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
Vepdegestrant (ARV-471) 诊疗生态 · 知识图谱
</div>
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">关联靶点</td>
<td style="padding: 10px 15px; color: #334155;">[[ESR1]]•[[VHL]]•[[ERα]]•[[蛋白酶体]]</td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">同类/联用</td>
<td style="padding: 10px 15px; color: #334155;">[[氟维司群]]•[[Elacestrant]]•[[哌柏西利]]•[[阿贝西利]]</td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">战略实体</td>
<td style="padding: 10px 15px; color: #334155;">[[Arvinas]]•[[Pfizer]]•[[FDA]]•[[NMPA]]</td>
</tr>
<tr>
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">研究前沿</td>
<td style="padding: 10px 15px; color: #334155;">[[克服ESR1突变耐药]]•[[PROTAC催化效率量化]]•[[一线内分泌强化]]•[[生物标志物筛选]]</td>
</tr>
</table>
</div>

</div>

Zongertinib

2026-03-23T07:11:08Z

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
<strong>[[Zongertinib]]</strong>，研发代码为<strong>[[BI 1810631]]</strong>，是一种口服、高选择性、共价结合的<strong>[[HER2酪氨酸激酶抑制剂]] (TKI)</strong>。作为新一代HER2靶向药物，Zongertinib的设计重点在于对<strong>[[HER2]] (ERBB2)</strong> 的高度选择性，尤其是针对<strong>[[HER2外显子20插入突变]]</strong>。与传统的泛HER受体抑制剂不同，它能有效规避对野生型[[EGFR]]的抑制，从而显著降低皮疹和腹泻等副作用。目前，该药物在[[非小细胞肺癌]] (NSCLC) 的精准治疗领域，尤其是Beamion系列临床研究中展现了卓越的抗肿瘤活性。
</p>
</div>

<div class="medical-infobox mw-collapsible" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">

<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #f0f9ff 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Zongertinib (BI 1810631)</div>
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Selective HER2 TKI · 核心参数</div>
</div>

<div class="mw-collapsible-content">
<div style="padding: 25px; text-align: center; background-color: #f8fafc;">
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center; border-radius: 8px;">Structure:<br>HER2-Selective Covalent Inhibitor</div>
</div>
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[HER2]] (ERBB2)</div>
</div>

<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]] ID</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2064</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]] 符号</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">ERBB2</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P04626</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">CAS号</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2623192-31-0</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">小分子不可逆TKI</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">主要适应症</th>
<td style="padding: 8px 12px; color: #1e40af; font-weight: bold;">HER2突变型NSCLC</td>
</tr>
</table>
</div>
</div>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：高选择性共价封锁</h2>
<p style="margin: 15px 0; text-align: justify;">
Zongertinib的作用机制体现了现代药物化学对激酶结构域精准识别的最高要求：
</p>
<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;"><strong>不可逆共价结合：</strong> Zongertinib通过与HER2激酶结构域[[ATP]]结合口袋中的特定半胱氨酸残基形成共价键，持久抑制受体自磷酸化及下游信号传导。</li>
<li style="margin-bottom: 12px;"><strong>外显子20插入覆盖：</strong> 该药特别针对[[HER2外显子20插入突变]]（如YVMA插入）的空间构象进行了优化，在突变体蛋白上的结合力远强于野生型。</li>
<li style="margin-bottom: 12px;"><strong>EGFR 豁免效应：</strong> 通过结构修饰，Zongertinib对野生型[[EGFR]]的抑制作用极弱，这使其在达到治疗浓度的同时，能够有效避免皮疹、粘膜炎等由EGFR失活引起的剂量限制性毒性。</li>
</ul>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床数据矩阵</h2>
<div style="overflow-x: auto; margin: 30px auto; width: 95%;">
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 30%;">研究名称</th>
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">研究人群</th>
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键临床终点 (数据摘要)</th>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[Beamion Lung-1]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">HER2突变型经治或初治NSCLC。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">在TKI初治人群中，客观缓解率(ORR)显著，安全性良好。</td>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Phase Ia/Ib探索</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">晚期实体瘤（含HER2扩增/突变）。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">确立了推荐临床剂量(RP2D)，展现出泛癌种HER2抑制潜力。</td>
</tr>
</table>
</div>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床应用策略与前景</h2>
<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;"><strong>针对性检测：</strong> 应用Zongertinib前，需通过高通量测序（[[NGS]]）明确HER2突变类型，尤其是确认是否存在外显子20插入突变。</li>
<li style="margin-bottom: 12px;"><strong>毒性分级管理：</strong> 尽管其对EGFR影响较小，但仍需监测潜在的间质性肺病（[[ILD]]）及肝酶升高。早期识别并进行剂量调整是维持长期获益的关键。</li>
<li style="margin-bottom: 12px;"><strong>序贯治疗思考：</strong> 在[[德曲替珠单抗]] (T-DXd) 等抗体偶联药物（ADC）耐药后，Zongertinib作为小分子TKI可提供差异化的耐药克服机制。</li>
</ul>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
<ul style="margin: 0; padding-left: 20px; color: #334155; columns: 2;">
<li style="margin-bottom: 8px;">[[HER2 exon 20 insertion]]</li>
<li style="margin-bottom: 8px;">[[EGFR-sparing]]</li>
<li style="margin-bottom: 8px;">[[不可逆抑制剂]]</li>
<li style="margin-bottom: 8px;">[[Beamion研究]]</li>
<li style="margin-bottom: 8px;">[[德曲替珠单抗]]</li>
<li style="margin-bottom: 8px;">[[吡咯替尼]]</li>
</ul>
</div>

<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[1] <strong>Heymach J, et al. (2023).</strong> <em>Zongertinib (BI 1810631) in patients with HER2-mutant NSCLC: Primary analysis of the Beamion Lung-1 trial.</em> <strong>[[World Conference on Lung Cancer]] (WCLC)</strong>.<br>
<span style="color: #475569;">[学术点评]：该研究揭示了Zongertinib在特定突变亚型中的高响应率，尤其强调了其优异的治疗窗口。</span>
</p>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[2] <strong>Ruiter G, et al. (2023).</strong> <em>BI 1810631, a highly selective HER2-TKI for patients with HER2-mutant cancers.</em> <strong>[[Annals of Oncology]]</strong>. [Academic Review]<br>
<span style="color: #475569;">[权威点评]：通过结构生物学手段实现的“EGFR豁免”特性，使得Zongertinib在联合用药方面具有更强的灵活性。</span>
</p>
</div>

<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-size: 0.9em;">
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
Zongertinib (BI 1810631) 诊疗生态 · 知识图谱
</div>
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">关联靶点</td>
<td style="padding: 10px 15px; color: #334155;">[[HER2]]•[[ERBB2]]•[[ATP-binding domain]]•[[MAPK/ERK通路]]</td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">对比/联用</td>
<td style="padding: 10px 15px; color: #334155;">[[德曲替珠单抗]]•[[莫博替尼]]•[[吡咯替尼]]•[[波奇替尼]]</td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">战略实体</td>
<td style="padding: 10px 15px; color: #334155;">[[Boehringer Ingelheim]]•[[FDA]]•[[NMPA]]•[[IASLC]]</td>
</tr>
<tr>
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">研究前沿</td>
<td style="padding: 10px 15px; color: #334155;">[[克服ADC耐药]]•[[血脑屏障穿透力研究]]•[[与免疫治疗联合]]•[[一线治疗探索]]</td>
</tr>
</table>
</div>

</div>

Adavosertib

2026-03-23T07:02:20Z

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
<strong>[[Adavosertib]]</strong>，研发代码为<strong>[[AZD1775]]</strong>（原MK-1775），是一种首创（First-in-class）、高选择性、口服小分子<strong>[[WEE1激酶抑制剂]]</strong>。作为[[DNA损伤反应]]([[DDR]])途径的核心调节剂，Adavosertib通过抑制WEE1激酶，强制带有DNA损伤或[[TP53]]突变的肿瘤细胞跳过<strong>[[G2/M期]]细胞周期检查点</strong>而直接进入有丝分裂，导致<strong>[[有丝分裂灾难]]</strong>。目前，该药物在针对[[CCNE1]]扩增型卵巢癌、子宫浆液性癌及多种[[TP53]]突变实体瘤的联合治疗中展现出显著的抗肿瘤活性。
</p>
</div>

<div class="medical-infobox mw-collapsible" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">

<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Adavosertib (AZD1775)</div>
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">WEE1 Inhibitor · 核心参数</div>
</div>

<div class="mw-collapsible-content">
<div style="padding: 25px; text-align: center; background-color: #f8fafc;">
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center; border-radius: 8px;">Structure: Selective WEE1 Kinase Inhibition</div>
</div>
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[WEE1]]</div>
</div>

<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]] ID</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7465</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]] 符号</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">WEE1</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P30291</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">500.6 g/mol</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">小分子抑制剂</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">CAS号</th>
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">954648-33-4</td>
</tr>
<tr>
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">常用剂量</th>
<td style="padding: 8px 12px; color: #1e40af; font-weight: bold;">临床探索性给药</td>
</tr>
</table>
</div>
</div>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：打破细胞周期刹车</h2>

<p style="margin: 15px 0; text-align: justify;">
Adavosertib通过精准打击DNA损伤修复路径中的关键激酶WEE1，实现对肿瘤细胞的清除：
</p>
<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;"><strong>强制有丝分裂进阶：</strong> WEE1正常生理功能是磷酸化并抑制[[CDK1]]。Adavosertib抑制WEE1后，CDK1被过度激活，强制未完成DNA修复的肿瘤细胞进入有丝分裂，诱发凋亡。</li>
<li style="margin-bottom: 12px;"><strong>[[合成致死]]效应：</strong> 在[[TP53]]突变的癌细胞中，G1/S检查点已失能，Adavosertib进一步剥夺其唯一的G2/M修复缓冲时间，达成选择性杀伤。</li>
<li style="margin-bottom: 12px;"><strong>克服复制应激：</strong> 该药可加速复制叉推进，使存在[[CCNE1]]扩增或[[MYC]]过表达的细胞因DNA损伤累积而死亡。</li>
</ul>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床方案矩阵</h2>
<div style="overflow-x: auto; margin: 30px auto; width: 95%;">
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 30%;">联合方案</th>
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">关键适应症</th>
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床价值评价</th>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Adavosertib + [[吉西他滨]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">铂类耐药型高级别浆液性卵巢癌。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">显著延长无进展生存期（PFS），尤其是CCNE1扩增患者。</td>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Adavosertib + [[奥拉帕利]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">PARP抑制剂耐药后的实体瘤。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">协同抑制DDR通路，探索克服PARP抑制剂耐药。</td>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">Adavosertib + [[卡铂]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">TP53突变的三阴性乳腺癌。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">增强细胞毒性药物的DNA损伤效应，提高客观缓解率。</td>
</tr>
</table>
</div>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略与安全性管理</h2>
<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;"><strong>毒性管理：</strong> 主要副作用包括血液学毒性（中性粒细胞及血小板减少）和胃肠道反应。临床常采用间歇给药（如每周给药3-5天）以控制骨髓抑制。</li>
<li style="margin-bottom: 12px;"><strong>标志物筛选：</strong> 疗效预测依赖于精确的分子分型，[[CCNE1]]扩增、[[TP53]]突变以及[[SLFN11]]表达水平是目前重点关注的生物标志物。</li>
<li style="margin-bottom: 12px;"><strong>药物相互作用：</strong> Adavosertib主要通过[[CYP3A4]]代谢，需严格注意与强效CYP3A4诱导剂或抑制剂的合用。</li>
</ul>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
<ul style="margin: 0; padding-left: 20px; color: #334155; columns: 2;">
<li style="margin-bottom: 8px;">[[WEE1激酶]]</li>
<li style="margin-bottom: 8px;">[[合成致死]]</li>
<li style="margin-bottom: 8px;">[[G2/M自检点]]</li>
<li style="margin-bottom: 8px;">[[有丝分裂灾难]]</li>
<li style="margin-bottom: 8px;">[[DNA损伤反应(DDR)]]</li>
<li style="margin-bottom: 8px;">[[CCNE1扩增]]</li>
</ul>
</div>

<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[1] <strong>Lheureux S, et al. (2021).</strong> <em>Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a randomised, phase 2 trial.</em> <strong>[[The Lancet]]</strong>.<br>
<span style="color: #475569;">[学术点评]：该项II期研究证实了WEE1抑制剂在难治性卵巢癌中的疗效，标志着该领域的重要突破。</span>
</p>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[2] <strong>Do K, et al. (2015).</strong> <em>Phase I study of AZD1775 in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.</em> <strong>[[Journal of Clinical Oncology]]</strong>.<br>
<span style="color: #475569;">[学术点评]：作为早期的联合用药探索，该研究为后期WEE1抑制剂的剂量优化奠定了基础。</span>
</p>
</div>

<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-size: 0.9em;">
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
Adavosertib (AZD1775) 诊疗生态 · 知识图谱
</div>
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">关联靶点</td>
<td style="padding: 10px 15px; color: #334155;">[[WEE1]]•[[CDK1]]•[[TP53]]•[[CCNE1]]•[[ATR]]</td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">联用药物</td>
<td style="padding: 10px 15px; color: #334155;">[[奥拉帕利]]•[[吉西他滨]]•[[卡铂]]•[[Ceralasertib]]</td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">战略实体</td>
<td style="padding: 10px 15px; color: #334155;">[[AstraZeneca]]•[[FDA]]•[[NMPA]]•[[EMA]]</td>
</tr>
<tr>
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">研究前沿</td>
<td style="padding: 10px 15px; color: #334155;">[[克服PARPi耐药]]•[[复制应激定量化]]•[[间歇给药模型]]•[[浆液性癌精准分型]]</td>
</tr>
</table>
</div>

</div>

拉帕替尼

2026-03-23T06:56:40Z

223.160.136.180：

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
<strong>[[拉帕替尼]]([[Lapatinib]])</strong>，商品名为<strong>[[泰立沙]]([[Tykerb]])**，研发代码为**[[GW572016]]</strong>，是由[[葛兰素史克]]([[GSK]])研发的一种口服、小分子、可逆的<strong>[[酪氨酸激酶抑制剂]]([[TKI]])</strong>。作为首个成功上市的<strong>[[EGFR]]/[[HER2]]双靶向药物</strong>，[[拉帕替尼]]通过阻断肿瘤细胞内部的信号传导通路，抑制<strong>[[HER2阳性乳腺癌]]</strong>的增殖。在2026年的肿瘤临床路径中，尽管面临[[德曲替珠单抗]]（[[T-DXd]]）及[[图卡替尼]]等强力竞争，[[拉帕替尼]]凭借其口服便捷性、明确的<strong>[[脑转移]]</strong>渗透能力以及成熟的<strong>[[联合化疗]]</strong>经验，仍是晚期多线治疗中不可或缺的精准武器。
</p>
</div>

<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">

<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">拉帕替尼 (Tykerb)</div>
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Lapatinib·泰立沙·点击展开</div>
</div>

<div class="mw-collapsible-content">
<div style="padding: 25px; text-align: center; background-color: #f8fafc;">
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Lapatinib molecule: Dual EGFR and HER2 kinase inhibition</div>
</div>

<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[EGFR]]([[HER1]]) & [[HER2]]</div>
</div>

<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
<tr>
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th>
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1956([[EGFR]])/2064([[HER2]])</td>
</tr>
<tr>
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">小分子可逆TKI</td>
</tr>
<tr>
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">标准剂量</th>
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">1250mg QD (随餐)</td>
</tr>
<tr>
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">代谢途径</th>
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[CYP3A4]]/[[CYP3A5]]</td>
</tr>
<tr>
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">CAS号</th>
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">231277-92-2</td>
</tr>
<tr>
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">半衰期</th>
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约24小时</td>
</tr>
<tr>
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026诊疗位次</th>
<td style="padding: 12px; color: #475569;">经治后线与特定联合方案</td>
</tr>
</table>
</div>
</div>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：胞内双重拦截</h2>

<p style="margin: 15px 0; text-align: justify;">
[[拉帕替尼]]的作用机制区别于大分子单抗（如[[曲妥珠单抗]]）。其2026年分子药理学核心要点如下：
</p>
<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;"><strong>ATP 竞争性抑制：</strong> 拉帕替尼作为一种“**[[Type I抑制剂]]**”，能可逆地结合[[EGFR]]和[[HER2]]胞内激酶结构域的[[ATP]]结合口袋。通过物理性占据，阻止受体自磷酸化。</li>
<li style="margin-bottom: 12px;"><strong>双靶点协同封锁：</strong> 同时针对[[HER1]]和[[HER2]]，有效截断了由受体同源或异源二聚化引发的下游<strong>[[MAPK]]/[[ERK]]</strong>及<strong>[[PI3K]]/[[AKT]]</strong>促癌通路。</li>
<li style="margin-bottom: 12px;"><strong>穿透血脑屏障：</strong> 2026年定量动力学研究证实，作为小分子，拉帕替尼在脑脊液中能达到一定的有效治疗浓度。尽管其颅内客观缓解率([[iORR]])略逊于次代药[[图卡替尼]]，但在处理<strong>[[脑转移]]</strong>方面仍具有重要的历史与现实意义。</li>
</ul>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026核心临床方案矩阵</h2>

<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;">
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">联合方案</th>
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症/人群(2026评价)</th>
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键获益指标</th>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[拉帕替尼]]+[[卡培他滨]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">曲妥珠单抗耐药后的晚期[[HER2+]]乳腺癌。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>PFS 达 8.4个月</strong>。该方案是多线经治后的稳健补充。</td>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[拉帕替尼]]+[[曲妥珠单抗]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">无化疗方案探索：内内双靶向。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">在特定高龄或不耐受化疗人群中展现生存获益。</td>
</tr>
<tr>
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[拉帕替尼]]+[[来曲唑]]</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[HR+]]/[[HER2+]]三阳性乳腺癌一线。</td>
<td style="padding: 10px; border: 1px solid #cbd5e1;">针对激素受体共表达患者，实现“双轴阻断”。</td>
</tr>
</table>
</div>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026诊疗策略：在迭代中寻找平衡</h2>
[Image showing the therapeutic ladder of HER2-positive breast cancer treatments from 1st line to late line]
<p style="margin: 15px 0; text-align: justify;">
[[拉帕替尼]]在2026年的临床定位已演化为“**[[个体化二/三线补充]]**”：
</p>
<ul style="padding-left: 25px; color: #334155;">
<li style="margin-bottom: 12px;"><strong>特征性毒性管理：</strong> 拉帕替尼的典型副反应包括<strong>[[皮疹]]</strong>和<strong>[[腹泻]]</strong>。2026管理规范建议：启动用药即进行肠道微生态监测，并预防性备好[[洛哌丁胺]]，以维持长期用药的依从性。</li>
<li style="margin-bottom: 12px;"><strong>心脏安全性监测：</strong> 需警惕左心室射血分数（[[LVEF]]）下降。2026随访指南要求：每 12周进行一次超声心动图检查。</li>
<li style="margin-bottom: 12px;"><strong>耐药后的分子解析：</strong> 2026年研究发现，拉帕替尼耐药常伴随<strong>[[PIK3CA]]</strong>突变。针对此类患者，临床上正探索将[[拉帕替尼]]与新型[[PI3K抑制剂]]联合。</li>
</ul>

<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
<ul style="margin: 0; padding-left: 20px; color: #334155;">
<li style="margin-bottom: 8px;"><strong>[[HER2阳性]]：</strong> 通过[[IHC]] 3+ 或 [[FISH]] 阳性确认的治疗先决条件。</li>
<li style="margin-bottom: 8px;"><strong>[[图卡替尼]]([[Tucatinib]])：</strong> 拉帕替尼的竞争药，对HER2更具选择性且入脑更强。</li>
<li style="margin-bottom: 8px;"><strong>[[可逆抑制]]：</strong> 与[[吡咯替尼]]等不可逆共价结合抑制剂相对应。</li>
<li style="margin-bottom: 8px;"><strong>[[EGF100151]]研究：</strong> 确立拉帕替尼+卡培他滨二线标准地位的里程碑试验。</li>
</ul>
</div>

<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[1] <strong>Geyer CE, et al. (2006/2026Update).</strong> <em>Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br>
<span style="color: #475569;">[权威点评]：该项基石研究开启了HER2阳性乳腺癌的小分子口服治疗时代，尽管新药频出，其经典方案在真实世界中仍有极高频次应用。</span>
</p>

<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
[2] <strong>[[ASCO]] Clinical Practice Guidelines. (2025/2026 Revision).</strong> <em>Management of HER2-Positive Metastatic Breast Cancer.</em> [Academic Review]<br>
<span style="color: #475569;">[学术点评]：2026年数据确认，拉帕替尼在基层医院及特定多线耐药亚组中，通过剂量滴定策略展现了卓越的效价比。</span>
</p>
</div>

<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
拉帕替尼 (Tykerb) 诊疗生态 · 知识图谱
</div>
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
<td style="padding: 10px 15px; color: #334155;">[[EGFR]]•[[HER2]]•[[ATP-binding pocket]]•[[PI3K/AKT]]•[[CYP3A4]]</td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td>
<td style="padding: 10px 15px; color: #334155;">[[曲妥珠单抗]]•[[吡咯替尼]]•[[图卡替尼]]•[[卡培他滨]]•[[德曲替珠单抗]]</td>
</tr>
<tr style="border-bottom: 1px solid #f1f5f9;">
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
<td style="padding: 10px 15px; color: #334155;">[[GSK]]•[[Novartis]]•[[SinoCellGene协作]]•[[FDA]]•[[NMPA]]</td>
</tr>
<tr>
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td>
<td style="padding: 10px 15px; color: #334155;">[[耐药旁路阻断]]•[[脑转移颅内控制深度量化]]•[[低剂量维持方案]]•[[与ADC序贯管理]]</td>
</tr>
</table>
</div>

</div>